Trial Profile
Neoadjuvant Chemotherapy With Docetaxel, Cisplatin Followed by Maintenance Therapy With the EGFR Inhibitor Erlotinib (Tarceva) in Patients With Stage I, II and III Non-Small Cell Lung Cancer Following Definitive Surgical Resection
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 28 Aug 2023
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Docetaxel (Primary) ; Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 23 Aug 2023 Planned End Date changed from 31 Oct 2023 to 31 Oct 2025.
- 23 Aug 2023 Planned primary completion date changed from 31 Oct 2023 to 31 Oct 2025.
- 31 Jan 2023 Planned End Date changed from 2 Oct 2022 to 31 Oct 2023.